Stay updated with breaking news from Biolase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the medical technology company’s stock. Other equities research analysts also recently issued research reports about the stock. Benchmark reaffirmed a speculative buy rating and set a $200.00 […] ....
Investment analysts at StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL – Get Free Report) in a report released on Thursday. The firm set a “sell” rating on the medical technology company’s stock. A number of other brokerages have also recently weighed in on BIOL. Lake Street Capital reduced their target price on shares of […] ....
BIOLASE, Inc. (NASDAQ:BIOL – Get Free Report) was the recipient of a large decline in short interest in July. As of July 15th, there was short interest totalling 3,110,000 shares, a decline of 44.4% from the June 30th total of 5,590,000 shares. Based on an average trading volume of 8,460,000 shares, the days-to-cover ratio is […] ....
/PRNewswire/ BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced that it held a special meeting of. ....
StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a research note published on Wednesday. The brokerage issued a sell rating on the medical technology company’s stock. BIOL has been the subject of several other reports. Benchmark reissued a speculative buy rating and issued a $2.00 price target on shares of BIOLASE […] ....